Criteria for re-irradiation
Deutsches Ärzteblatt international · 2024
DOI: 10.3238/arztebl.m2024.0156 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Deutsches Ärzteblatt international, 2024. Verfasst von Jonas Willmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Otorhinolaryngology, Head and …. Hauptthemen laut MEDLINE: Re-Irradiation, Prostatic Neoplasms, Neoplasm Recurrence, Local, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: The treatment options for patients with progressive malignant tumors despite primary radiotherapy are often limited. In selected cases, re-irradiation can be offered. This article concerns the selection criteria and results of re-irradiation for certain types of cancer. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed, with particular attention to glio - blastoma, head and neck tumors, and prostatic carcinoma. RESULTS: The published studies of re-irradiation are few in number and often of limited methodological quality. For glioblastoma, a randomized controlled trial (RCT) found that adding re-irradiation to treatment with bevacizumab yielded no significant improvement in either median progression-free survival or median overall survival (hazard ratio [HR] 0.73; p = 0.05 and HR 0.98; p = 0.46, respec - tively). Re-irradiation is a treatment option for locoregional recurrences of head and neck tumors after primary radiotherapy, but it carries a risk of serious side effects. For unresectable recurrences of nasopharyngeal carcinoma, an RCT has shown that hyperfractionated re-irradiation is more effective than normofractionated re-irradiation (overall survival: HR 0.54, p = 0.014). For locally recurrent prostatic carcinoma after radiotherapy, re-irradiation can yield good oncologic outcomes with an acceptable level of urogenital and gastrointestinal side effects (5-year recurrence-free survival: stereotactic body radiation therapy (SBRT), 58%; high dose rate (HDR) brachytherapy, 77%; versus salvage prostatectomy, 72%). RCTs on this topic are lacking. CONCLUSION: Re-irradiation is a treatment option for selected cancer patients. As the available scientific evidence is limited, multidisciplinary collaboration and participatory decision-making are particularly important.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany…
Zitieren
APA
Willmann, J., Andratschke, N., Klußmann, J. P., Gschwend, J. E., Tabatabai, G., & Niyazi, M. (2024). Criteria for re-irradiation. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.m2024.0156
Vancouver
Willmann J, Andratschke N, Klußmann JP, Gschwend JE, Tabatabai G, Niyazi M. Criteria for re-irradiation. Deutsches Ärzteblatt international. 2024. doi:10.3238/arztebl.m2024.0156
BibTeX
@article{Willmann2024,
author = {Willmann, Jonas and Andratschke, Nicolaus and Klußmann, Jens Peter and Gschwend, Jürgen E and Tabatabai, Ghazaleh and Niyazi, Maximilian},
title = {Criteria for re-irradiation},
journal = {Deutsches Ärzteblatt international},
year = {2024},
doi = {10.3238/arztebl.m2024.0156}
}
EUVIMED